Quarter Ended: March 2026
Suven Life Sciences Limited – Q4 FY26 Results
NSE
suven
BSE
530239
Suven Life Sciences reported continued consolidated losses in Q4 FY26 despite a sharp rise in other income, as elevated R&D expenditure continued to weigh heavily on profitability.
key financial highlights
- Revenue from Operations:
- Revenue (Q4 FY26): ₹152.01 Lakhs
- QoQ Change: -45.88%
- YoY Change: +3.61%
- Previous Quarter (Q3 FY26): ₹280.87 Lakhs
- Previous Year (Q4 FY25): ₹146.70 Lakhs
- Revenue (Q4 FY26): ₹152.01 Lakhs
- Profit After Tax (PAT):
- PAT (Q4 FY26): – ₹4,559.55 Lakhs Loss
- QoQ Change: +55.27%
- YoY Change: -3.76%
- Previous Quarter (Q3 FY26): – ₹10,192.18 Lakhs Loss
- Previous Year (Q4 FY25): -₹4,394.49 Lakhs Loss
- PAT (Q4 FY26): – ₹4,559.55 Lakhs Loss
- QoQ Performance:
- Revenue Trend: Sharp Sequential Decline
- Profit Trend: Loss Reduction QoQ
Margin Analysis
Drivers:
- Extremely high R&D expenditure
- Weak operating revenue base
- Dependence on non-operating income
- Elevated employee and scientific research costs
- Research-focused business model
Insight:
- R&D expenses remain substantially larger than operating revenue, keeping profitability under pressure.
Segment insight
Business Summary:
The company continues operating primarily as a research-oriented life sciences business focused on long-term drug discovery and development.
Key Characteristics:
- High research intensity
- Low commercial revenue contribution
- Significant cash deployment into R&D
- Long gestation business model
- Earnings volatility linked to research spending
Earning quality check
Key Drivers:
- Other income contributed significantly to total income
- Core operational revenue remained limited
- R&D expenses dominated cost structure
- Continued negative profitability
- Losses remain operational in nature
Interpretations:
- Earnings quality remains weak due to dependence on non-core income and continued operating losses.
balance sheet Analysis
- Total Assets: ₹62,421.40 Lakhs
- Total Liabilities: ₹3,281.43 Lakhs
Insight:
- The company maintains a strong balance sheet with substantial equity funding and low liabilities despite continued losses.
key risks
- Persistent operating losses
- High R&D cash burn
- Weak revenue visibility
- Dependence on research commercialization
- Negative operating cash flow
- Biotechnology execution and approval risks
management strategy signals
Focus Area:
- Drug discovery and development
- Continued R&D investment
- Intellectual property development
- Long-term scientific pipeline creation
- Capital-backed research expansion
Financial metrics table
| Particular | Q4 FY26 | Q.O.Q | Y.O.Y |
|---|---|---|---|
| Total Income | ₹829.79 Lakhs | +48.63% | +208.53% |
| PBT | ₹-4,559.55 Lakhs | +55.27% | -3.76% |
| PAT | ₹-4,559.55 Lakhs | +55.27% | -3.76% |
Suven Life Sciences continues to operate in a high-investment research phase with persistent losses and weak operating revenue. While quarterly losses narrowed sequentially due to reduced R&D expenditure and strong other income, the company’s core profitability profile remains under pressure.
The strong balance sheet and low liabilities provide financial flexibility, but sustainable improvement depends on successful commercialization and monetization of its research pipeline.
Official Exchange Filing: Suven Life Sciences Limited
FISCAL YEAR
2025-2026
AUDIT STATUS
REVIEWED